Buy-and-Build in Healthcare Services: A Playbook for Middle-Market Investors

Buy-and-build has become the default value-creation strategy in middle-market healthcare services, and for good reason. The fragmentation of the sector creates a long runway of acquisition targets, scale genuinely improves most of these businesses, and a well-executed program can transform a single good company into a regional or national platform that commands a higher valuation. The strategy is sound. The execution is where it succeeds or fails, and in healthcare the failure modes are specific enough to name.

Start with the right platform

Everything downstream depends on the platform company, and the most common mistake is choosing it poorly. The platform is not simply the largest available target or the cheapest. It is the business with infrastructure capable of absorbing others: a real management team, financial systems that produce trustworthy numbers, a compliance function that can survive scrutiny, and a clinical or operational model worth replicating.

A platform with weak infrastructure cannot integrate acquisitions no matter how attractive those targets are; bolting healthy add-ons onto a shaky foundation simply distributes the weakness. It is usually worth paying more for a genuinely strong platform than acquiring a marginal one cheaply, because the platform's quality sets the ceiling on everything that follows. Time spent building platform capability before the acquisition pace accelerates is rarely wasted.

Build the integration capability before you need it

The defining risk of buy-and-build is integration, and it is almost always underestimated. A model can show beautiful accretion from add-ons, but the model does not capture the operational reality of merging billing systems, electronic health records, payer contracts, compliance regimes, compensation structures, and cultures. Each acquisition that is not properly integrated becomes a liability rather than an asset, and a backlog of half-integrated deals can quietly stall an otherwise promising platform.

The disciplined approach is to treat integration as a core competency built deliberately, not improvised under deadline. That means a repeatable playbook, a dedicated integration function, defined timelines for bringing each acquisition onto common systems, and the willingness to slow the acquisition pace when integration falls behind. Doing fewer deals well consistently beats doing more deals poorly. In healthcare, where billing errors and compliance lapses carry regulatory consequences, sloppy integration is not merely inefficient; it is dangerous.

Discipline on price and pace

A buy-and-build thesis often rests on multiple arbitrage: acquiring add-ons at lower multiples than the platform will eventually be valued at. That arbitrage is real, but it is not a license to overpay, and it erodes as a sector matures and sellers grow sophisticated. The moment a program starts paying platform-level multiples for add-ons, the core logic weakens and the margin for error thins.

Pace deserves equal discipline. There is real pressure, internal and external, to deploy capital and show acquisition momentum, and that pressure has pushed more than one platform into deals it should have passed on. The better operators stay willing to walk away from targets that are too expensive, too complex, or too distant from the platform's capabilities. The pipeline is long; patience is affordable; a bad acquisition is not.

Manage the risks that are specific to healthcare

Several risks are sharper in healthcare than in generic services buy-and-build. Reimbursement exposure means each target's payer mix and rate structure must be diligenced individually, because a target that looks accretive at its current rates may not be after they normalize. Labor matters acutely: an acquisition is only as valuable as its ability to retain the clinicians and staff who deliver the care, and a deal that triggers an exodus of key providers can destroy more value than it adds.

Compliance and regulatory diligence cannot be a checkbox. Billing practices, licensing, corporate-practice-of-medicine considerations, and prior regulatory history all carry real consequences, and inherited liabilities have a way of surfacing at the worst time. And cultural fit, easy to dismiss as soft, is in practice a hard determinant of retention and integration success. The targets that integrate smoothly tend to share the platform's operating values; the ones that do not tend to fight every system change.

Our experience points to a simple conclusion. Buy-and-build in healthcare services is among the most effective value-creation strategies available to middle-market investors, but it is unforgiving of haste and weak infrastructure. The platforms that succeed are built on strong foundations, integrate as a core discipline, stay honest on price and pace, and treat reimbursement, labor, and compliance risk as first-order concerns rather than afterthoughts. Executed that way, buy-and-build creates durable institutions. Executed carelessly, it creates expensive collections of unintegrated practices. The difference is entirely in the discipline.